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Bezafibrate suppresses rat antiglomerular basement membrane
crescentic glomerulonephritis.
Background. The immunoregulatory activity of ligands for
peroxisome proliferator-activated receptors (PPARs) has been
recently paid attention. The regulatory effect of bezafibrate
(BZF), a ligand for PPARa on glomerulonephritis was investi-
gated using a rat anti-glomerular basement membrane (GBM)
glomerulonephritis model.
Methods. The effect on development of anti-GBM glomeru-
lonephritis was examined by treatment with BZF from day −7
to day 7 after intravenous injection of rabbit anti-GBM serum
into Wistar Kyoto (WKY) rats. The therapeutic efficacy after
onset of the glomerulonephritis was also checked by treatment
with BZF from day 3 to 7. On day 7, the condition was evalu-
ated histologically. The expression of a tissue injury molecule,
macrophage metalloesterase (MME), was measured by North-
ern blot analysis. The suppressive effect on immune cells was as-
sessed by proliferation assay with mitogen-stimulated rat spleen
cells.
Results. Histopathologic changes induced by anti-GBM in
rats treated with BZF (day −7 to day 7) were markedly sup-
pressed in a dose-dependent fashion. Infiltration of ED-1+
macrophages in glomeruli, proteinuria, and mRNA expression
of MME in kidneys were diminished in parallel with histologic
improvement. Moreover, the disease activity was also attenu-
ated even by the treatment after onset of the glomerulonephri-
tis (day 3 to 7). The mitogen-induced proliferation of spleen
cells was down-regulated at concentrations of BZF, which were
equivalent to those in sera of BZF-treated rats.
Conclusion. BZF markedly suppresses the activity of rat anti-
GBM crescentic glomerulonephritis. Fibrates might serve as a
therapeutic option for crescentic glomerulonephritis.
The peroxisome proliferators-activated receptors
(PPARs) are ligand-activated transcription factors and
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a member of the nuclear receptor superfamily [1]. There
are three isoforms of PPAR including a, b , and c, which
are differentially expressed in types of cells and tissues
[2, 3]. PPARs are activated after binding of ligands, form
heterodimers with retinoid receptors and bind to PPAR
response elements in the promoters of target genes,
whose products are involved in lipid metabolism, glucose
homeostasis, cell proliferation, and cell differentiation
[2, 3]. Recently, anti-inflammatory action of PPARs
has been highlighted [3–10]. Fibrates, which are known
as synthetic PPARa ligands, are widely used as lipid-
lowering drugs. With respect to their suppressive effects
on inflammation, there are some studies using inflamma-
tory models such as reactive amyloidosis in mice [11] and
autoimmune myocarditis in rats [12]. On the other hand,
there are various reports showing their regulatory mech-
anisms in kinds of immune systems in vitro [13, 14].
Antiglomerular basement membrane (GBM)
glomerulonephritis characterized by crescent for-
mation and necrotizing inflammation of glomerular
capillary is the most severe form of glomerulonephritis.
The glomerulonephritis induced by injection of rabbit
anti-GBM serum in Wistar Kyoto (WKY) rats is a
model of this disease. Until today, a number of critical
factors, such as complements, proinflammatory cy-
tokines, chemokines, intercellular adhesion molecule-1
(ICAM-1), CD8+ lymphocytes and macrophages/mono-
cytes (Mø/Mo), for the development of the anti-GBM
glomerulonephritis have been revealed [15–20]. The
glomerular injury is completely suppressed by deletion
of CD8+ lymphocytes [16], showing the crucial role
of cellular components in this model. In addition, we
have recently reported that macrophage metalloelastase
(MME), which was produced by infiltrating Mø, was a
potent factor for glomerular injury in this model [21].
In early phase of the glomerulonephritis, CD8+ lympho-
cytes appear in glomeruli, peaking 3 days after anti-GBM
serum injection, and enhance the expression of adhesion
molecules on glomerular endothelial cells by releasing
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proinflammatory cytokines and chemokines. Mø/Mo
appear later and participate in developing crescentic
glomerulonephritis [18, 20].
Here we report that a fibrate, bezafibrate (BZF),
markedly suppresses the development of the crescentic
glomerulonephritis model. Results reported in this study
might suggest that BZF, which is being used worldwide
for lowering lipids, could be applied for the treatment of
crescentic glomerulonephritis.
METHODS
Experimental design and animals
Male WKY/NCrj rats (7 weeks old) were purchased
from Charles River Japan (Yokohama, Japan). Animal
care was performed in accordance with the guidelines
of Niigata University. Rats were randomly divided into
four groups. Each group included six rats. On day −7, two
groups started to receive BZF (44, 133, or 400 mg/kg/day)
by gavage, twice per day, and continued to receive BZF
until end. BZF was kindly provided by Kiisei Pharmaceu-
tical Co., Ltd. The dose of administration was determined
by previous experiments using rodents [11, 22]. Another
group received only vehicle (0.05% carboxymethyl cel-
lulose) in a same fashion. The other group received
neither (negative control). On day 0, rats in the three
groups, except for the negative control, were injected in-
travenously with rabbit anti-GBM serum (200 lL, con-
taining about 2 mg IgG), which was prepared as previ-
ously described [16, 19]. On day 6, rats were placed in
metabolic cages for 24 hours for urine collection, and
concentrations of total protein and creatinine in urine
were measured. On day 7 after anti-GBM serum injec-
tion, 7 hours after the first administration of BZF in the
day, rats were bled under anesthesia by diethyl ether in-
halation and sacrificed after removal of kidneys. Renal
tissues were snap frozen or fixed in 10% formalin. As
for investigating the therapeutic effect of BZF on the
glomerulonephritis after the disease induction, rats were
divided into three groups. Treatment with either vehicle
(N = 6) or BZF (400 mg/kg/day) (N = 6) was started
from day 3 after anti-GBM serum injection and contin-
ued until end (day 7). The negative control group (N = 6)
received neither anti-GBM serum injection nor BZF ad-
ministration. Urine and kidney samples were collected
by the same way as described above.
Histologic evaluation
Renal tissues fixed in 10% formalin, embedded in
paraffin, were cut into 10 lm sections, and stained with
periodic acid-Schiff (PAS) for histologic analysis. About
100 glomeruli were evaluated and the percentage of
glomeruli accompanied by necrotizing glomerulitis or
crescent formation was quantitated by two independent
observers in a blind fashion.
Immunohistochemistry
For detection of rabbit Ig deposition in glomeruli,
frozen sections of kidney tissues were quenched with
0.3% hydrogen peroxide and treated with goat antirab-
bit Ig-conjugated peroxidase-labeled polymer (Dako,
Carpinteria, CA, USA) for 30 minutes. For detec-
tion of ED-1 or CD8, paraffin sections were quenched
and incubated with mouse antirat ED-1 monoclonal
antibody (Serotec, Oxford, UK) or mouse antirat
CD8 (Cosmo Bio, Tokyo, Japan) monoclonal anti-
body for 60 minutes at room temperature, followed by
goat antimouse Ig-conjugated peroxidase-labeled poly-
mer (Dako). The calorimetric reaction was developed
with 3,3′-diaminobenzidine tetrahydrochloride (DAB)
(Dako) and counterstaining was performed with hema-
toxylin. Thirty glomeruli were evaluated and the number
of ED-1+ or CD8+ cells in glomerulus was counted by
two independent observers in a blind fashion.
Measurement of serum parameters
Values of creatinine, total cholesterol, and triglyceride
were determined enzymatically. The concentration of
BZF in serum was measured using high-performance liq-
uid chromatography (HPLC) with a Tosoh ODS 80TM
column [23].
Estimation of antirabbit Ig antibody levels in serum
Antirabbit Ig antibody titer in rat serum was deter-
mined by enzyme-linked immunosorbent assay (ELISA)
as described previously [21]. Briefly, 1/100 diluted sera
from rats were incubated on wells coated with normal
rabbit IgG (500 ng) followed by blocking with 0.5%
bovine serum albumin (BSA). After washing, wells were
then incubated with 1/4000 diluted horseradish peroxi-
dase (HRP)-conjugated goat antirat IgG + monoclonal
antibody. The colorimetric reaction using tetramethyl-
benzidine product was quantified by measuring the ab-
sorbance at 450 nm. Normal rat serum and serum from
the rat immunized with rabbit Ig were used as a negative
and a positive control, respectively.
Northern blot analysis
Total RNA was isolated from whole kidneys of each
experimental groups using RNA extraction solution (Iso-
gen, Nippon Gene, Tokyo, Japan). Total RNA was loaded
on 1.5% agarose gel, transferred onto nylon membrane
(Hi-bond N) (Amersham Biosciences Corp., Piscataway,
NJ, USA) and hybridized with a 32P-labeled cDNA probe
for rat MME (the same one as previously described[21]).
As an internal control, glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) expression was detected on the
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Fig. 1. Bezafibrate (BZF) suppresses the development of antiglomerular basement membrane (GBM) glomerulonephritis. Photomicrographs were
representative kidney sections on day 7. The severity of anti-GBM glomerulonephritis was markedly attenuated by the treatment with more than
133 mg/kg of BZF, whereas rabbit anti-GBM Ig was equally deposited along capillary walls of glomeruli. (A) Paraffin sections were stained with
periodic acid-Schiff (PAS). Panel a, Untreated normal rats (negative control; without injection of anti-GBM or BZF treatment). Panel b, Positive
control rats (with injection of anti-GBM, without BZF treatment). Panel c, Diseased rats treated with BZF at 44 mg/kg. Panel d, At 133 mg/kg.
Panel e, At 400 mg/kg (original magnification ×200). (B) Rabbit anti-GBM Ig deposited along the glomerular capillary wall was detected in frozen
sections by antirabbit Ig peroxidase system. Photomicrographs in panels f to j were from the same kidneys as panels a to e in (A), respectively
(original magnification ×200). (C) The percentage of diseased glomeruli accompanied by necrotizing glomerulitis and/or crescentic formation in
kidney sections from each group was evaluated in around 100 glomeruli (N = 6). ∗P < 0.001; ∗∗P < 0.01 vs. the positive control group. Error bars
represent SE.
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Fig. 2. Bezafibrate (BZF) inhibits the infiltration of ED-1+ cells in glomeruli. (A) Paraffin sections from each group were stained with antirat
ED-1 antibodies. High numbers of ED-1+ infiltrates were observed in glomeruli of positive control rats (panel b). The infiltration of ED-1+ cells
were unchanged in rats with lower dose of BZF (44 mg/kg) (panel c), but clearly diminished in rats with 133 or 400 mg/kg of BZF (panel d or
panel e, respectively). Especially, the infiltration in rats treated by 400 mg/kg of BZF (panel e) was markedly suppressed and almost equal to that
in negative control rats (panel a) (original magnification ×200). (B) Thirty glomeruli were evaluated and the number of ED-1+ cells in glomerulus
were counted. The values were means of the numbers (N = 6). ∗P < 0.001; ∗∗P < 0.01 vs. the positive control group. Error bars represent SE. GBM
is glomerular basement membrane.
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Fig. 3. Bezafibrate (BZF) decreases the excretion of urinary protein.
The amount of protein in urine (mg/dL) on day 6 was standardized by
that of creatinine in urine (mg/dL) in the groups (N = 6). ∗P < 0.01;
∗∗P < 0.05 vs. the positive control group. Error bars represent SE.
same membrane. After measuring the radio-intensities
by Bas 2000 (Fuji film), the relative ratios of MME ex-
pression to GAPDH expression were standardized by the
value of positive control.
Cell proliferation assays
Spleens were harvested from normal rats and prepared
into single cell suspensions with a metal screen. Red blood
cells were lysed by incubation in a hypotonic solution
(0.83% NH4Cl and 20 mmol/L Tris, pH 7.6). Cells were
washed twice in phosphate-buffered saline (PBS) and
suspended in RPMI 1640 supplemented with 10% heat-
inactivated fetal calf serum (FCS). Cells were cultured
at 1 × 106 cells/well in 96-well plates (No.353072) (BD
Falcon, Ijamsville, MD, USA) with BZF at 0, 30, 100,
or 300 lmol/L and simultaneously with Con A (Sigma
Aldrich Japan, Tokyo, Japan) at 0 or 5 lg/mL. The cells
were pulsed with 1 lCi/well [3H]-thymidine (Amersham
Biosciences Corp.) at 48 hours and harvested 24 hours
later. The incorporated [3H]-thymidine was counted in a
b-scintillation counter.
Statistical analysis
The results are expressed as means ± SE. The signif-
icance of differences between parameters of the groups
were tested with unpaired or paired Student t test.
RESULTS
BZF suppresses the development of anti-GBM
glomerulonephritis
Figure 1A shows typical histologic features of
glomeruli from each group 7 days after injection of
anti-GBM serum. Severe pathologic changes such as
necrotizing glomerulitis, crescent formation, mesan-
gial/endocapillary cell proliferation, and glomerular hy-
pertrophy were observed in rats injected with anti-GBM
serum (positive control) (Fig. 1A, panel b). In rats treated
with more than 133 mg/kg/day of BZF, especially with its
higher dose (400 mg/kg/day), the induction of glomeru-
lonephritis was attenuated in both severity and extent of
diseased glomeruli (Fig. 1A, panels d and e), whereas rab-
bit Ig was equally deposited along glomerular capillaries
in the groups injected with anti-GBM serum (Fig. 1B).
The percentage of diseased glomeruli was evaluated in
Figure 1C, resulting in a significant reduction of glomeru-
lar injury in groups treated with more than 133 mg/kg of
BZF in a dose-dependent fashion. Since the importance
of ED-1+ Mø and CD8+ lymphocytes in the develop-
ment of this disease model was revealed in previous stud-
ies [16, 18–21], the infiltration of the cells into glomeruli
was examined using immunohistochemistry (Fig. 2A).
The number of ED-1+ cells per glomerulus on day 7 de-
creased in the groups treated with more than 133 mg/kg
of BZF (Fig. 2B). A small number of CD8+ cells were ob-
served in glomeruli of positive controls and rats treated
with 44 mg/kg of BZF on day 7, but not in rats effec-
tively treated with BZF (data not shown). Moreover, the
amount of urinary protein on day 6 significantly dimin-
ished in rats treated with the higher doses of BZF (Fig. 3)
in parallel with the attenuation of glomerular injuries.
These data indicated that BZF effectively suppressed the
development of anti-GBM glomerulonephrits in a dose-
dependent manner at doses more than 133 mg/kg.
There were no dead rats in any groups during the exper-
iment. Although fibrates are known to induce liver injury
in rodents at toxic doses [24], there was no abnormality
in livers by macroscopic and microscopic observations,
even in rats treated with the highest dose of BZF (data
not shown). The other parameters on day 7 were summa-
rized in Table 1. A representative renal function, creati-
nine clearance, was slightly impaired in the diseased rats
and tended to be improved in the BZF-treated groups,
but there were not significant differences. Serum creati-
nine levels were not significantly different. Spleens cells
harvested from rats treated with the highest dose of BZF
were fewer than those of positive controls, whereas the
number of leukocytes in peripheral blood was not sig-
nificantly different among the groups. The parameters of
lipid profiles, total cholesterol and triglycerides, of BZF-
treated groups decreased compared with untreated dis-
eased rats. Body weights of BZF-treated rats at 400 mg/kg
diminished compared with those of positive controls. The
levels of BZF in sera of rats treated with 133 or 400 mg/kg
at 7 hours after the last administration on day 7 were 68.2
or 127.7 lg/mL (188 or 353 lmol/L; FW of BZF, 361.83),
respectively. In the anti-GBM glomerulonephritis model,
host antibodies against heterologous rabbit Ig fixed to rat
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Table 1. The characteristics of the experimental groups
Peripheral blood Spleen Creatinine Total Body
white blood cells cells Creatinine clearance cholesterol Triglyceride weight Bezafibrate
Groups ×102 cells/lL ×107 cells/spleen mg/dL mL/min mg/dL mg/dL g lg/mL
Negative control ND 25.0 ± 2.9 0.24 ± 0.01 135 ± 28 80.0 ± 0.9 67.0 ± 4.5 275.8 ± 2.4 ND
Anti-GBM injection +
vehicle only
73.0 ± 8.0 23.3 ± 3.0 0.30 ± 0.04 80 ± 19 122.2 ± 4.4 113.7 ± 11.8 244.5 ± 2.1 ND
Anti-GBM injection +
BZF 44 mg/kg/day
ND ND 0.27 ± 0.05 95 ± 19 ND ND 243.1 ± 4.5 ND
Anti-GBM injection +
BZF 133 mg/kg/day
65.8 ± 5.5 20.1 ± 2.1 0.22 ± 0.01 116 ± 11 81.5 ± 5.4a 54.3 ± 4.0a 239.5 ± 4.7 68.2 ± 4.6
Anti-GBM injection +
BZF 400 mg/kg/day
62.0 ± 1.1 9.2 ± 2.5b 0.22 ± 0.02 111 ± 9 60.4 ± 2.2a 39.8 ± 6.7a 192.8 ± 8.4a 127.7 ± 5.5
GBM, glomerular basement membrane; BZF, bezafibrate, serum levels of BZF at 7 hrs after the last administration; ND, not determined.
aP < 0.01; bP < 0.05 vs. positive control (anti-GBM injection + vehicle) rats.
GBM start to participate in glomerular injury from day 5
to 7 (autologous phase) [15]. However, the antirabbit Ig
Ab titers in sera on day 7 were low and were not signifi-
cantly different among the groups (data not shown).
BZF started even after the induction of anti-GBM
glomerulonephritis attenuates the disease
Next, we attempted to examine whether treatment with
BZF was also effective even after onset of the glomeru-
lonephritis. Anti-GBM serum was injected (on day 0) and
the rats were treated with either vehicle or BZF (400 mg/
kg/day) from day 3 to day 7. On day 3, when BZF was
started, glomerular injuries such as glomerular cell pro-
liferation was already marked (Fig. 4A). On day 7, the
glomerular injury in the BZF-treated rats was clearly mild
when compared with vehicle-treated controls, whereas
rabbit Ig was equally deposited along glomerular capil-
laries (Fig. 4B and C). The infiltration of ED-1+ cells
in glomeruli was also reduced in the BZF-treated rats
(Fig. 5). The amount of proteinuria from the BZF-treated
rats on day 6 was significantly lower than that of vehicle-
treated controls (Fig. 6).
Reduced expression of MME
in kidneys of BZF-treated rats
We previously found MME as a tissue injury molecule
in the early phase of this glomerulonephritis model [21].
To examine whether BZF reduced the expression of
MME in kidneys of diseased rats, Northern blot anal-
yses were performed. As shown in Figure 7, mRNA
expression of MME, which was induced in diseased kid-
neys, decreased in groups effectively treated with BZF
in accordance with the attenuation of glomerular injury.
This finding suggested that BZF suppressed anti-GBM
glomerulonephritis, at least in part, by down-regulation
of MME expression in kidneys.
BZF suppresses mitogen-induced proliferation
of spleen cells
Fibrates are known to regulate various immune reac-
tions [3, 7, 25, 26] and are now considered as more general
immunosuppressive agents [27]. Then, in order to inves-
tigate whether the attenuation of anti-GBM glomeru-
lonephritis was exerted by immunosuppressive activity of
BZF, we carried out proliferation assay using normal rat
spleen cells as responders and Con A as a mitogen. The
thymidine-incorporation into spleen cells stimulated by
mitogen was strongly suppressed by BZF at 30 lmol/L or
greater as shown in Figure 8. This finding indicated that
BZF had an antiproliferative effect on immune cells at
concentrations equivalent to, or less than, those in sera
of rats effectively treated with BZF.
DISCUSSION
This study showed the suppressive effect of BZF on
the development of rat anti-GBM glomerulonephritis.
The disease activity of the glomerulonephritis evaluated
by histologic appearance and proteinuria was attenuated
not only by the pretreatment, but also by the treatment
even after onset of the disease. The infiltration of ED-1+
Mø/Mo into glomeruli, and the expression of a glomeru-
lar injury molecule, MME, in kidneys were diminished in
rats treated with BZF. The proliferation of spleen cells
stimulated by mitogen was inhibited in vitro by BZF at
concentrations equivalent to those in sera of rats effec-
tively treated with BZF.
Fibrates are known as synthetic ligands for PPARa and
their ability of lipid control and immune regulation are
mediated through the activation of PPARa [28]. As for
immune regulation, fibrates suppressed the expression of
inflammatory mediators induced by cytokines in various
types of cells in vitro [14, 28]. The solid evidence for im-
munoregulatory effects of PPARa was shown by experi-
ments using PPARa-deficient animals. The inflammatory
responses to lipopolysaccharide (LPS) and the allergic
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Fig. 4. Bezafibrate (BZF) suppresses
antiglomerular basement membrane (GBM)
glomerulonephritis even after induction of
the disease. (A) The photomicrograph was
the glomerulus on day 3 after injection of
anti-GBM serum. The crescent formation
and necrosis of glomerular capillaries were
already obvious. The administration of BZF
(400mg/kg) was started from day 3 (original
magnification ×200). (B) Photomicrographs
were representative kidney sections on day
7. The severity of anti-GBM nephritis was
attenuated by the treatment with BZF (panel
b vs. panel c). Panel a, Untreated normal
rats (negative control; without injection
of anti-GBM or BZF treatment). Panel
b, Positive control rats (with injection of
anti-GBM, without BZF treatment). Panel c,
Diseased rats treated with BZF at 400 mg/kg
from day3 to 7. Photomicrographs detecting
rabbit anti-GBM Ig deposition (panels d to
f) were from the same kidneys as panels a
to c, respectively. Rabbit anti-GBM Ig was
equally deposited along capillary walls of
glomeruli in diseased rats with or without
BZF treatment (panels e and f) (original
magnification ×200). (C) The percentage of
the diseased glomeruli in kidney sections
from each group was evaluated in around 100
glomeruli (N = 6). ∗P < 0.001 vs. the positive
control group. Error bars represent SE.
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Fig. 5. Bezafibrate (BZF) started from day 3 diminishes infiltration
of ED-1+ cells. (A) Paraffin sections from each group were stained
with anti-rat ED-1 antibody. ED-1+ infiltrates were diminished in BZF-
treated rats (panel c) when compared with positive control rats (panel
b). Panel a, untreated normal rats (original magnification ×200). (B)
Thirty glomeruli were evaluated and the number of ED-1+ cells in the
glomerulus were counted. The values were means of the numbers (N =
6). ∗P < 0.001 vs. the positive control group. Error bars represent SE.
GBM is glomerular basement membrane.
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Fig. 6. Bezafibrate (BZF) started from day 3 diminishes the excretion
of urinary protein. The amount of protein in urine (mg/dL) on day 6
was standardized by that of creatinine in urine (mg/dL) in the groups
(N = 6). ∗P < 0.05 vs. the positive control group. Error bars represent
SE. GBM is glomerular basement membrane.
inflammation were enhanced in PPARa-deficient mice
[25, 29, 30]. In addition, fibrates did not suppress
the induction of proinflammatory cytokines in PPARa-
deficient mice, demonstrating that the effect was
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Fig. 7. Bezafibrate (BZF) down-regulates
mRNA expression of macrophage metalloe-
lastase (MME). (A) The expression of MME
mRNA in whole kidneys was detected by
Northern blot. The numbers below indicate;
negative control rats (lane 1), diseased rats
treated with 0 (lane 2), 133 (lane 3), or 400
mg/kg of BZF (lane 4) from day −7 to 7,
and diseased rats treated with 0 (lane 5) or
400 mg/kg of BZF (lane 6) from days 3 to
7. The MME expression (upper panel) was
up-regulated in the diseased kidneys (lanes
2 and 5) and reduced in kidneys effectively
treated with BZF (lanes 3, 4, and 6). The ex-
pression of glyceraldehyde-3-phosphate de-
hydrogenase (GAPDH) was also shown as an
internal control (lower panel). The data were
the representative of three independent ex-
periments. (B) The radioactivity of bands was
measured by BAS2000 (Fuji film) and the rel-
ative expression ratio (MME/GAPDH) was
demonstrated by standardizing with values of
the positve control group (lane 2) (untreated
diseased rats) (N = 3). ∗P < 0.01; ∗∗P < 0.05.
Error bars represent SE.
PPARa-dependent [25]. PPARa and its ligands, fi-
brates, exerted anti-inflammatory actions by interfering
with signal transductions of cytokines, including nu-
clear factor-jB (NF-jB) and activating protein (AP-1)
pathways [13, 25, 29]. Recently, it was proposed that a fi-
brate, WY14643, might be considered as an immunosup-
pressive agent since it suppressed more general activities
of immune cells, including mitogen-activated prolifera-
tion and antigen-specific IgG production [27]. Because
effective levels of BZF in serum and culture of experi-
ments in our current study were equivalent to those em-
ployed in the previous reports with BZF or other fibrates
[25–27, 31, 32], the suppressive effect of BZF on anti-
GBM glomerulonephritis might be brought about by
these immunoregulatory abilities as a fibrate. In addition,
it is possible that BZF inhibited signaling events elicited
by proinflammatory cytokines in renal resident cells as
well, such as glomerular endothelial cells, podocytes, and
proximal tubular cells. Since there have recently been
reports showing PPARa and/or b were expressed in
these cells [2, 33, 34], BZF might suppress responses of
glomerular resident cells against the action of proinflam-
matory cytokines released from activated immune cells;
for example, production of chemokines/cytokines and ex-
pression of adhesion molecules in glomeruli, which could
promote local inflammation further. Moreover, because
PPARa expressed in proximal tubules plays an important
role in maintaining basic cell functions, such as reabsorp-
tion of albumin [35], and fibrates protect tubular cells
from ischemia [36] and cisplatin-induced acute renal fail-
ure [37], BZF might maintain tubular functions and re-
duce proteinuria through activating PPARa in these cells
under the inflammatory condition.
Part of immunosuppressive actions by WY14643, were
recently reported to be independent of PPARa path-
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Fig. 8. Bezafibrate (BZF) suppresses mitogen-stimulated proliferation
of immune cells. Spleen cells from normal rats (1 × 106/well in 96-well
plates) were cultured with or without Con A (5 lg/mL) in the presence
of BZF at 0 (vehicle only), 30, 100, or 300 lmol/L. Fold induction was the
ratio of thymidine uptake in cells with Con A to that without Con A in
culture. The graph is a representative of three independent experiments
(N = 4). ∗P < 0.001; ∗∗P < 0.01 vs. wells of vehicle only. Error bars
represent SE.
way [27]. When compared with the findings presented
in studies with WY14643 [27, 32], the present results
with BZF seemed to be compatible with those, in terms
of decreasing number of spleen cells in vivo and in-
hibiting mitogen-activated proliferation of spleen cells in
vitro. However, it could not be clarified in the present
study whether antiglomerulonephritis activity of BZF
was dependent on the PPARa pathway because it was
not carried out using PPARa-deficient animals. Recently,
it has been reported that, in contrast to WY14643, the
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expression of genes induced by BZF was partly mediated
by PPARb although mainly mediated by PPARa [38].
The antiglomerulonephritis activity of BZF could be de-
pendent on PPARb pathway. It could be considered, in
either case, that BZF suppressed the glomerulonephritis
by inhibiting immune reactions against heterologous Ig
fixed to GBM, including Mø/Mo activation accompanied
by expression of tissue injury molecules such as MME.
BZF reduced mRNA expression of MME in kidneys,
which was strongly induced in the glomerulonephri-
tis model. It was unclear whether BZF directly down-
regulated the transcription of MME gene in Mø/Mo or
the reduction was caused by decreased number of infil-
trating Mø/Mo. However, since MME was exclusively ex-
pressed in infiltrating Mø/Mo in this model, which was
reported in our previous study [21], and the number of
infiltrating Mø/Mo decreased in effectively BZF-treated
rats in parallel with decline of MME mRNA expression,
the MME depression might be mainly derived from the
decreased number of infiltrating Mø/Mo.
This glomerulonephritis model was attempted to treat
with BZF in a previously published paper [39]. In that
study, BZF was administered at 50 mg/kg without any in-
hibitory effect on the development of glomerulonephri-
tis. No significant efficacy was observed at such dose by
our hands (44 mg/kg), either. The inhibitory effect on the
glomerulonephritis appeared only at 133 mg/kg or more
as shown in this study. Also in other papers using ro-
dent disease models, anti-inflammatory effects of fibrates
were shown around 150 mg/kg or more [11, 22, 40]. More-
over, in the present study, it was demonstrated that the
glomerulonephritis was suppressed at 100 to 400 lmol/L
of BZF in serum, which was compatible with other reports
[22, 25–27, 31, 32]. In addition, there were no abnormal
findings in livers of rats treated even with the highest dose
of BZF (400 mg/kg) although fibrates induce liver injury
at toxic doses in rodents [24].
CONCLUSION
BZF suppressed the development of rat anti-GBM
glomerulonephritis, even if administered after the induc-
tion of the glomerulonephritis. The therapeutic effect
might be exerted by the immunosuppressive action of
fibrates, which has been already demonstrated in systems
both in vivo and in vitro. The treatment options for cres-
centic glomerulonephritis are currently limited to use of a
few drugs such as steroids and cyclophosphamide for anti-
inflammation. The findings in this study might have sig-
nificant therapeutic implications for crescentic glomeru-
lonephritis. The feasibility of the clinical application of
fibrates for the treatment of human glomerulonephritis
accompanying diffuse or focal crescent formation might
need to be considered. However, a number of issues,
for example, what is the appropriate dose for obtain-
ing the therapeutic effects in human, must be, of course,
determined.
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